October 27, 2025 — Washington, D.C.
The U.S. Food and Drug Administration (FDA) has posted multiple Class II medical device recalls affecting widely used surgical consumables and diagnostic imaging systems. The recalls, announced on October 27, 2025, include ICU Medical’s ChemoLock Vial Spikes and Philips Medical Systems’ CT 5300 scanners, both of which play critical roles in oncology infusion and intraoperative imaging workflows.
These actions stem from identified product defects that may pose moderate health risks if not mitigated—including equipment leaks and software malfunctions affecting imaging accuracy. For surgical supply managers and biomedical engineers, the implications are immediate: facilities must audit inventories, assess device integrity, and coordinate with manufacturers for replacements or field corrections.
1. ICU Medical Recall: ChemoLock Vial Spikes (20 mm)
ICU Medical voluntarily recalled specific lots of its ChemoLock Vial Spike (20 mm), citing weld separation at the port, which can lead to liquid leaks during chemotherapy preparation or administration. The product is widely used in oncology infusion centers, inpatient pharmacy settings, and ORs supporting onco-surgery services.
According to the FDA recall notice, the defect could compromise sterility, introduce contamination, and expose healthcare workers to hazardous drugs. Affected lot numbers were distributed in mid-2025 and include items commonly ordered via GPOs and pharmacy wholesalers.
2. Philips Medical Systems Recall: CT 5300 Scanner Line
Philips recalled several models in its CT 5300 series, including systems deployed in hybrid operating rooms, interventional radiology suites, and trauma centers. The issue relates to a software malfunction in version 6.2.1, which may cause image misregistration or system freezing during scan acquisition—both of which could delay diagnosis or intraoperative decision-making.
The FDA classified this as a Class II recall, meaning the defect could cause temporary or medically reversible adverse health consequences. Philips has initiated field actions including remote software patches and optional on-site technician visits, depending on customer service agreements.
These two recalls, though distinct in function, present cascading operational impacts across surgical departments, radiology suites, and hospital pharmacy teams:
a) Disruption to Oncology Support Services
• ChemoLock devices are integral to safe chemotherapy compounding and administration. Any compromise in their sterility or performance poses risks not only to patients but to staff handling cytotoxic agents.
• Oncology surgical programs—particularly those involving intraoperative chemotherapy (HIPEC, IP therapy)—may need to adjust protocols or source alternative transfer devices urgently.
b) Imaging Workflow Interruptions
• Philips CT 5300 systems are used for surgical navigation, especially in neurosurgery, trauma, and spine procedures where intraoperative imaging guides decisions.
• A software fault that interferes with scan fidelity or system uptime can delay cases, reduce OR throughput, and increase anesthesia time—factors that directly affect quality metrics and operating costs.
c) Procurement and Biomedical Engineering Response
• Both recalls demand immediate inventory identification, quarantine of affected lots, and submission of serial numbers or logs to manufacturers.
• Biomedical teams may be required to reprogram scanners, apply patches, or coordinate swaps under vendor-managed service agreements.
Hospital and ASC procurement departments managing sterile consumables and capital imaging systems
